Background {#Sec1}
==========

Malaria remains a major disease of public health concern worldwide, particularly in sub-Saharan Africa \[[@CR1]\]. In 2018, the World Health Organization (WHO) estimated 228 million cases and 405,000 deaths caused by malaria worldwide, mostly in children aged younger than 5 years \[[@CR1]\]. Infections of the *Plasmodium* species usually present as monoinfection by one species; however, mixed infections by more than one species within one individual can occur \[[@CR2]--[@CR6]\]. The interactions between mixed infections are not well characterized, but may play roles in disease progression and outcomes \[[@CR7]\]. Moreover, mixed infections by *Plasmodium* species are often not recognized or are underestimated by microscopists \[[@CR8]\]. In Asia, mixed infections by *Plasmodium* species have occurred at a frequency of 2% to 30% \[[@CR9]\]. Although mixed infection by two *Plasmodium* species has been recognized, mixed infection by three different *Plasmodium* species within one individual has not been clarified.

This study sought to determine the pooled prevalence and proportion of triple mixed infection by *Plasmodium* spp. compared with double mixed infection. This information is necessary to guide the progress of research on mixed infection and malaria management, as well as control strategies for strategic malaria diagnostic service choices and treatment options.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Articles from PubMed, Scopus, and Web of Science were searched for cross-sectional studies on triple mixed infection by *Plasmodium* species in patients with all species of malaria. Triple mixed infection were defined as infection with three *Plasmodium* species. Articles published between February 2, 1907, and February 24, 2020, in the English language were included in the analysis if they explicitly reported the presence of triple mixed infection by *Plasmodium* species. The search strategy included the search terms "(Plasmodium OR Malaria) AND ("Mixed infection" OR "Triple infection")" (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Selection criteria {#Sec4}
------------------

Observational studies, prospective cohorts, and case--control designs were included if they reported triple mixed malaria infection among the included participants by polymerase chain reaction (PCR) or molecular methods. Studies were excluded if the numbers of triple mixed infection could not be extracted and if only one species of *Plasmodium* was studied or evaluated subsequently from microscopy or rapid diagnostic test (RDT). Animal studies, clinical drug trials, case reports, experimental studies, reviews, systematic reviews, and polymorphism studies were excluded because they were considered incompatible study designs for the present review and meta-analysis. Studies were selected and identified by two independent authors (MK and KUK), with discrepancies resolved following discussion with a third author (FM). The protocol of this analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Data extraction and definitions {#Sec5}
-------------------------------

The data extracted for individual studies included author names, year of publication, study area, year of study, details, and numbers of the participants, age ranges, blood collection methods, DNA extraction method, investigated gene, PCR method, malaria positivity status, number of double mixed infections, and number of triple mixed infections. The numbers of patients with four different *Plasmodium* species were also extracted for further discussions in the present study. Subgroup analyses were performed for the following parameters: publication year (before and after 2000), continent (Asia, Africa, America, Europe, or Oceania), participant group (febrile patients and residents from the same community), type of blood storage for PCR (EDTA blood or dried blood spots), and age group of patients with mixed infection.

Data analysis {#Sec6}
-------------

The primary outcome was the pooled proportion and pooled prevalence of triple mixed infection by *Plasmodium* species, with random-effects meta-regression used to investigate these pooled analyses. The analyses were performed using Stata Statistical Software (Release 15; StataCorp LLC. USA). The secondary outcomes were differences in the pooled proportion between triple mixed infection and dual mixed infection by *Plasmodium* species reported in the included studies. Those differences were estimated using random-effects meta-analysis to calculate the odds ratio (ORs) and 95% confidence intervals (CI). The analyses were performed using Review Manager 5 (RevMan 5, Cochrane Community).

Potential bias related to individual studies was assessed using a tool developed by the Newcastle-Ottawa Scale (NOS) to assessing the quality of non-randomized studies in meta-analyses. The quality of included studies was rated if they qualified with a maximum of 7 stars. Publication bias related to study effects was assessed by funnel plot asymmetry. Between-study heterogeneity was assessed by the I^2^ statistic and was assessed using the random-effects statistic. Subgroup analysis of the baseline characteristics included continent (Asia, Africa, America, Europe, or Oceania), participants (residents and febrile individuals), type of blood storage for PCR (EDTA blood or dried blood spots), and age group. For the subgroup analyses of age groups and different mixed infections (double and triple infection), the age groups of patients were classified as ≤ 5 and \> 5 years because children younger than 5 years are one of the most vulnerable groups affected by malaria \[[@CR10]\].

Results {#Sec7}
=======

Characteristics of the included studies {#Sec8}
---------------------------------------

After screening the titles and abstracts of 5621 identified studies published between February 2, 1907, and February 24, 2020, the full texts of 344 (6.11%) potentially relevant studies were reviewed (Fig. [1](#Fig1){ref-type="fig"}). There were 309 studies that did not meet the inclusion criteria, mostly because they did not document triple mixed infection by *Plasmodium* species in their studies. Thirty-five (10.1%) of 344 studies could be extracted and were included in the analysis (Table [1](#Tab1){ref-type="table"}). Of the 35 studies, 14 (40%) were from the Asia--Pacific region, 9 (25.7%) were from Africa, 5 (14.3%) were from Europe, 4 (11.4%) were from Oceania, and three (8.6%) were from the (Table [1](#Tab1){ref-type="table"}). Among 35 included studies from 22 different countries, most (4/35, 11.4%) were from Papua New Guinea \[[@CR11]--[@CR14]\], Cambodia \[[@CR15]--[@CR17]\], India \[[@CR6], [@CR18], [@CR19]\], Italy \[[@CR4], [@CR20], [@CR21]\], and Uganda \[[@CR2], [@CR22], [@CR23]\]. Most of the participants included among the studies were residents (16/35, 45.7%), febrile patients (11/35, 31.4%), and malaria-positive cases (6/35, 17.1%). Twenty-four studies (68.6%) reported age ranges, whereas others did not. One study used samples from doubtful microscopic examination \[[@CR18]\], whereas another enrolled both febrile and asymptomatic patients to perform PCR analysis \[[@CR6]\]. More than half of the included studies (18/35, 51.4%) used EDTA blood to extract the DNA for PCR analysis, whereas others used dried blood spots (15/35, 42.9%), and one study used thick smears for DNA extraction \[[@CR24]\]. Most of the studies (28/35, 80%) used DNA commercial kits, while four studies (4/35, 11.4%) used 30% Chelex-100 and phenol--chloroform extraction for DNA extraction. All of the included studies used the *18S ribosomal RNA* (rRNA) gene to identify the *Plasmodium* genus and species. Overall, 44,310 participants were enrolled in the included studies. Of those, most were residents (34,483, 77.8%), febrile patients (7797, 17.6%), and malaria-positive samples (1675, 3.78%).Fig. 1Flow chart for the study selectionTable 1Characteristics of the included studiesNo.Author, yearStudy area\
(years of the survey)ParticipantsAge rangeAge groups (n)Blood storage for PCRDNA extractionInvestigated genePCR methodMalaria positive by PCRMixed infection (dual infection)Mixed infection (Triple infection)1.Asua et al. \[[@CR2]\]UgandaMalaria positive (499)6 months to 10 yearsDried blood spotsChelex extraction kits18S rRNANested PCR474Pf/Pm (19)Pf/Po (14)Pf/Pv (3)Pm/Pv (1)Total = 37Pf/Pm/Po (1)2.Barber et al. \[[@CR3]\]Malaysia (2009--2011)Malaria positive (653)*P. knowlesi* (IQR 20--50 years),*P. falciparum* (IQR 9--31 years),*P. vivax*(19 years, IQR 7--32 years)Triple infection: \< 5 (1), 10--14 (1), 30--34 (1), 80--84 (1)Dual infection: \< 5 (1), 5--9 (2), 10--14 (5), 15--19 (3), 20--24 (2), 25--29 (2), 30--34 (4), 35--39 (3), 40--44 (5), 45--49 (2), 50--54 (2), 70--74 (2), 75--79 (1)NANA18S rRNANested PCR445Pv/Pk (36)Pf/Pk (6)Pm/Pk (1)Pf/Pm (1)Total = 44Pf/Pv/Pk (2)Pv/Pm/Pk (2)3.Calderaro et al. \[[@CR4]\]Italy (2000--2007)Febrile patients (701)NAEDTA bloodHigh Pure Template Preparation kit (RocheDiagnostics, Mannheim, Germany)18S rRNANested PCR159Pf/Po (3)Pf/Pm (1)Total = 4Pf/Pm/Po (2)4.Camargo-Ayala et al. \[[@CR5]\]Colombia (2012--2015)Febrile patients (671)\< 5, 5--18, 18--60, and \> 60 yearsTriple infection: \< 5 (4), 5--18 (2), 18--60 (6), \> 60 (2)Dual infection: \< 5 (16), 5--18 (56), 18--60 (139), \> 60 (15)EDTA bloodPure Link Genomic DNA mini kit (Invitrogen)18S rRNANested PCR531Pv/Pm (190)Pf/Pv (25)Pf/Pm (10)Total = 225Pf/Pm/Pv (14)5.Dhangadamajhi et al. \[[@CR6]\]India (2008)Febrile and asymptomatic (242)0--5 years, 6--15, and \> 15 yearsTriple infection: 0--5 (1), 6--15 (2), \> 15 (2)Dual infection: 0--5 (7), 6--15 (32), \> 15 (39)EDTA bloodPhenol--Chloroform extraction18S rRNANested PCR197Pf/Pv (15)Pf/Pm (54)Pv/Pm (10)Total = 79Pf/Pm/Pv (5)6.Dormond et al. \[[@CR40]\]Switzerland (2004--2008)Malaria positive (89)\>16 yearsEDTA bloodMagNA Pure LC DNA isolation kit (Roche, Basel, Switzerland)18S rRNANested PCR89Pf/Po (3)Pf/Pm (2)Total = 5Pf/Pm/Po (1)7.Fuehrer et al. \[[@CR41]\]Bangladesh:Chittagong Hill Tracts (2007--2008)Malaria Research InitiativeBandarban field site (2008--2009)Febrile patients (379)Any ageDried blood spotsModified Chelex-based technique, the InstaGene Whole BloodKit (Bio-Rad Laboratories, Hercules, CA)18S rRNANested PCR189Pf/Pv (21)Pf/Pm (2)Total = 23Pf/Pm/Pv (2)8.Gabrielli et al. \[[@CR42]\]Congo (2014)Residents(306)1 week to \< 5 yearsDried blood spotsThe commercialkit Dried Blood spot DNA isolation Kit (Norgen BiotekCorp, Ontario, Canada)18S rRNANested PCR164Pf/Pm (13)Pf/Po (2)Pf/Pv (1)Total = 16Pf/Pm/Pv (1)9.Hopkins et al. \[[@CR22]\]Uganda (2010--2011)Residents (272)5--81 years: 5--10, 11--20, and ≥ 21 yearsEDTA bloodPhenol--Chloroform extraction18S rRNANested PCR and qPCR199Pf/Pm (38)Pf/Po (8)Total = 46Pf/Pm/Po (10)10.Jiang et al. \[[@CR43]\]Myanmar (2008)Malaria positive (146)NADried blood spotsChelex extraction kits18S rRNANested PCR146Pf/Pk (13)Pv/Pk (13)Pf/Pv (10)Total = 36Pf/Pv/Pk (2)11.Kasehagen et al. \[[@CR11]\]Papua New Guinea (2001--2003)Residents (16,209)\< 2, 2.0--3.9, 4.0--6.9, 7.0--9.9, 10.0--19.9, 20.0--39.9, and ≥ 40 yearsEDTA bloodQIAamp 96 DNA Blood Kit (QIAGEN, Valencia, CA)18S rRNALDR-FMA658Pf/Pv (72)Pf/Pm (32)Pf/Po (13)Pv/Pm (17)Pv/Po (9)Pm/Po (4)Total = 147Pf/Pm/Pv (28)Pf/Pv/Po (5)Pf/Pm/Po (4)Pv/Pm/Po (4)Pf/Pv/Pm/Po (11)12.Krishna et al. \[[@CR18]\]India (2015)Doubtful microscopic (355)≤ 1, \> 1--4, \>4--8, \> 8--14, and \> 14 yearsDried blood spotsFavorPrep Genomic DNA Mini Kit (Favorgen Biotech Corp., Taiwan).18S rRNANested PCR353Pf/Pv (59)Pf/Pm (3)Total = 62Pf/Pm/Pv (5)Pf/Pv/Po (1)Pf/Pv/Pm/Po (1)13.Lorenzetti et al. \[[@CR44]\]Brazil (2003--2005)Malaria positive (115)18--52 yearsEDTA bloodPhenol--Chloroform extraction18S rRNANested PCR115Pf/Pm (2)Pf/Pv (28)Total = 30Pf/Pm/Pv (1)14.Marques et al. \[[@CR45]\]Mozambique (2001--2002)Residents (308)1--82 yearsEDTA bloodPhenol--Chloroform extraction18S rRNANested PCR115Pf/Pm (70)Pf/Po (10)Total = 80Pf/Pm/Po (9)15.May et al. \[[@CR48]\]Nigeria (1996--1997)Residents (593)Children in Abanla (1--11 years), Children in Ibadan (3--8 years), Children in health centres in Ibadan (0.8--11 years), Healthy adults (15--56 years)EDTA bloodDNA-Easy Kit (Invitrogen, St. Louis, MO)18S rRNANested PCR165Pf/Pm (41)Pf/Po (12)Total = 53Pf/Pm/Po (27)16.Mehlotra et al. \[[@CR13]\]Papua New Guinea (1998--1999)Residents (1848)All groups \< 1--85 years: 2--4, 5--9, ≥ 10 yearsTriple infection: 2--4 (2), 5--9 (8), ≥ 10 (24)Dual infection: 2--4 (14), 5--9 (51), ≥ 10 (115)EDTA bloodQIAamp 96 spin blood kits(QIAGEN, Valencia, CA)18S rRNANested PCR541Pf/Pv (116)Pf/Pm (27)Pf/Po (11)Pv/Pm (21)Pv/Po (4)Pm/Po (3)Total = 182Pf/Pm/Pv (23)Pf/Pv/Po (9)Pf/Pm/Po (1)Pf/Pv/Pm/Po (3)17.Mehlotra et al. \[[@CR12]\]Papua New Guinea (1996)Malaria positive (173)5--10 and \> 11 yearsTriple infection: 5--10 (1), \> 11 (0)Dual infection: 5--10 (6), \> 11 (9)EDTA bloodQIAamp 96 or individual spin bloodkits (QIAGEN, Valencia, CA)18S rRNANested PCR163Pf/Pv (40)Pf/Pm (16)Pf/Po (4)Pv/Pm (3)Total = 63Pf/Pm/Pv (27)Pf/Pv/Po (8)Pf/Pm/Po (5)Pv/Pm/Po (1)Pf/Pv/Pm/Po (9)18.Mueller et al. \[[@CR14]\]Papua New Guinea (2005)Residents (2527)\< 10 and ≥ 20 yearsEDTA bloodQIAmp 96 DNA Blood kits (Qiagen, CA)18S rRNAA semi-quantitative post-PCR, ligase detection reaction/fluorescent microsphere assay (LDR-FMA)1844Pf/Pv (363)Pf/Pm (136)Pf/Po (27)Pv/Pm (26)Pv/Po (7)Pm/Po (1)Total = 560Pf/Pm/Pv (99)Pf/Pv/Po (33)Pf/Pm/Po (8)Pv/Pm/Po (6)Pf/Pv/Pm/Po (17)19.Nino et al. \[[@CR46]\]Colombia (2015--2016)Febrile patients (1392)NAEDTA bloodPure Link Genomic DNA mini kit (Invitrogen)18S rRNANested PCR596Pf/Pv (111)Pv/Pm (340)Pf/Pm (29)Total = 480Pf/Pm/Pv (52)20.Pati et al. \[[@CR19]\]IndiaFebrile patients (1589)Severe malaria (15--65 years)Dried blood spotsChelex extraction kits18S rRNANested PCR110Pf/Pv (11)Pf/Pm (4)Pv/Pm (3)Total = 18Pf/Pm/Pv (5)21.Perandin et al. \[[@CR20]\]ItalyFebrile patients (122)NAEDTA bloodThe High Pure PCR template preparation kit (Roche, Indianapolis,Ind.)18S rRNANested PCR62Pf/Po (1)Pf/Pm/Po (1)22.Peruzzi et al. \[[@CR21]\]Italy (2005--2006)Febrile patients (139)2--49 yearsTriple infection: 19 yearsEDTA bloodHigh Pure PCR TemplatePreparation Kit" (Roche)18S rRNANested PCR36NonePf/Pm/Po (1)23.Pongvongsa et al. \[[@CR28]\]Laos-Vietnam border (2010)Residents (3059)Sample for PCR (135)*P. knowlesi* (2--15 years)Triple infection (Pf/Pv/Pk): mean 6.43 years (7)Dual infection (Pk/Pv): mean 7.4 years (5)Dried blood spotsQIAamp DNA micro kit(QIAGEN, Tokyo, Japan)18S rRNANested PCR90Pf/Pv (15)Pf/Pm (2Pv/Pk (5)Total = 22Pf/Pm/Pv (1)Pf/Pv/Pk (7)24.Putaporntip et al. \[[@CR25]\]Thailand (2006--2007)Febrile patients (1874)1--81 yearsDried blood spotsQiagen DNA Mini Kit18S rRNANested PCR1751Pf/Pv (200)Pf/Pm (6)Pf/Po (2)Pf/Pk (5)Pv/Pm (8)Pv/Po (4)Pv/Pk (4)Pm/Po (1)Total = 230Pf/Pm/Pv (4)Pf/Pv/Po (7)Pf/Pv/Pm/Po (1)25.Rubio et al. \[[@CR38]\]Spain (1997--1998)Febrile patients (168)NAEDTA bloodModified Chelex-based technique, the InstaGene Whole BloodKit (Bio-Rad Laboratories, Hercules, CA)18S rRNANested PCR89Pf/Pm (4)Pf/Po (1)Pf/Pv (3)Total = 8Pf/Pm/Pv (1)26.Rubio et al. \[[@CR39]\]Equatorial Guinea (1996)Febrile patients (159)\< 6 yearsDried blood spots5% Chelext-100 Resin (Bio-Rad Laboratories,Hercules, CA)18S rRNANested PCR126Pf/Pm (36)Pf/Po (3)Pf/Pv (2)Total = 41Pf/Pv/Po (3)27.Sitali et al. \[[@CR29]\]Zambia (2012)Residents (873)\< 6 yearsDried blood spotsChelex extraction kits18S rRNANested PCR474Pf/Pm (31)Pf/Po (10)Pf/Pv (1)Total = 42Pf/Pm/Po (6)Pf/Pm/Pv (1)28.Sluydts et al. \[[@CR15]\]Cambodia (2012)Residents (5793)2--5, 5--14, 15--39, and ≥ 40 yearsDried blood spotsInstagene^®^ Matrix resin (Bio-Rad, Singapore)18S rRNATwo-step Real-time PCR368Pf/Pv (56)Pf/Pm (5)Pf/Po (1)Pv/Pm (3)Pv/Po (11)Total = 76Pf/Pm/Pv (4)Pf/Pv/Po (1)Pf/Pv/Pm/Po (1)29.Steenkeste et al. \[[@CR16]\]Cambodia (2001)Residents (337)NADried blood spotsthe Instagene resin (Bio-Rad,USA)18S rRNANested PCR140Pf/Pv (52)Pf/Pm (15)Pf/Po (4)Total = 71Pf/Pv/Po (7)Pf/Pm/Pv (24)Pf/Pv/Pm/Po (8)30.Steenkeste et al. \[[@CR17]\]Cambodia (2001)Residents (134)\< 1-- \> 60 years: \< 1, 1, 2, 3, 4, 5--9, 10--14, 15--19, 20--39, 40--60, and \> 60 yearsDried blood spotsInstagene resin (Bio-Rad, Germany) a18S rRNANested PCR102Pf/Pm (4)Pf/Po (2)Pf/Pv (18)Pv/Pm (3)Total = 27Pf/Pm/Pv (7)Pf/Pv/Po (3)Pf/Pv/Pm/Po (3)31.Subissi et al. \[[@CR23]\]Uganda (2010)Residents (509)1--5, 6--10, and \> 20 yearsTriple infection: 1--5 (5), 6--10 (5), \> 20 (0)Dual infection: 1--5 (27), 6--10 (24), \> 20 (2)Dried blood spotsQIAamp mini kit (QIAGEN, Venlo, The Netherlands)18S rRNANested PCR299Pf/Pm (39)Pf/Po (14)Total = 53Pf//Pm/Po (10)32.Toma et al. \[[@CR27]\]Laos (1997)Residents (336)\< 11-- \> 50 years: 2--68 years in Phavang and 0--75 years in SisomsouenEDTA bloodGFX Genomic Blood DNA PurificationKit (Pharmacia Biotech).18S rRNANested PCR117Pf/Pv (19)Pf/Pm (2)Pv/Pm (2)Pv/Po (1)Total = 24Pf/Pm/Pv (1)Pf/Pv/Po (1)Pf/Pv/Pm/Po (1)33.Woldearegai et al. \[[@CR47]\]Gabon (2016)Residents (834)1--96 years: 1--5, 6--10, 11--15, 16--20, 21--25, 26--30, 31--40, 41--50, 51--60, 61--70, 71--80, and 81--96 yearsEDTA bloodQIAsymphony DSP DNA kit18S rRNANested PCR618Pf/Pm (123)Pf/Po (43)Pm/Po (1)Total = 167Pf//Pm/Po (51)34.Zhou et al. \[[@CR24]\]Thailand (1995--1996)Residents (548)NAThick smear30% Chelex-10018S rRNANested PCR114Pf/Pv (10)Pf/Pm (6)Pv/Pm (19)Pv/Po (1)Total = 36Pf/Pm/Pv (49)Pf/Pv/Po (2)Pv/Pm/Po (1)Pf/Pv/Pm/Po (7)35.Zhou et al. \[[@CR26]\]China (2008--2012)Febrile patients (562)NADried blood spotsQIAampDNA Mini Kit (QIAGEN China (Shanghai)18S rRNANested PCR384Pf/Pv (67)Pv/Po (2)Pf/Pk (2)Pf/Pm (2)Po/Pm (1)Total = 74Pf/Pv/Po (3)Pf/Pm/Pv (1)Pv/Pm/Po (1)Pf/Pv/Pm/Po (1)Total = 12,0232 species = 3059Pf/Pv = 1318Pf/Po = 188Pf/Pm = 775Pf/Pk = 26Pv/Pm = 645Pv/Po = 39Pv/Pk = 58Pm/Po = 10Pm/Pk = 13 species = 601Pf/Pm/Pv = 355Pf/Pv/Po = 83Pf/Pm/Po = 137Pf/Pv/Pk = 11Pv/Pm/Po = 13Pv/Pm/Pk = 24 species = 53Pf refers to *P. falciparum*Pv refers to *P. vivax*Po refers to *P. ovale*Pm refers to *P. malariae*Pk refers to *P. knowlesiNA* Not Assessed

Regarding the number of malaria-positive participants by PCR, 12,023 patients were infected by one of the five *Plasmodium* species (*Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale*, and *Plasmodium knowlesi*). Among those positive patients, 3059 (25.4%) were infected with two different *Plasmodium* species. The most common types of mixed infection were *P. falciparum* and *P. vivax* (1318, 11%), *P. falciparum* and *P. malariae* (775, 6.4%), and *P. vivax* and *P. malariae* (645, 5.4%). Among those 12,023 positive patients, 601 (5%) were infected with three different *Plasmodium* species. The most common types of mixed infection were *P. falciparum*/*P. malariae*/*P. vivax* (355, 3%), *P. falciparum*/*P. malariae*/*P. ovale* (137, 1.1%), and *P. falciparum*/*P. vivax*/*P. ovale* (83, 0.7%). Fifty-three patients (0.44%) had quadruple mixed infection with *P. falciparum*/*P. vivax*/*P. malariae/P. ovale*.

Quadruple mixed infection was identified among the present studies and comprised of *P. falciparum*/*P. vivax/P. malariae*/*P. ovale* in one individual. Fifty-three patients (0.44%) had quadruple mixed infection. Most (40/53, 75.5%) were found in Papua New Guinea \[[@CR11]--[@CR14]\], followed by Cambodia (12/53, 22.6%) \[[@CR15]--[@CR17]\], Thailand (8/53, 15%) \[[@CR24], [@CR25]\], India (1/53, 1.9%) \[[@CR18]\], China (1/53, 1.9%) \[[@CR26]\], and Laos (1/53, 1.9%) \[[@CR27]\].

Quality of the included studies {#Sec9}
-------------------------------

All of the included studies were rated with a maximum of 7 stars (Table [2](#Tab2){ref-type="table"}). Sixteen studies received 7 stars, 12 received 6 stars, and 7 received 5 stars. The twelve studies rated with 6 stars used febrile controls, and the 7 studies rated with 5 stars used malaria-positive samples for PCR analysis.Table 2Quality of the included studiesNo.ReferencesSelectionCompatibilityExposureTotal score (7)Is the case definition adequate?Representativeness of the casesSelection of controlsDefinition of controlsAscertainment of exposureSame method of ascertainment for cases and controlsNon-response Rate1.Asua et al. \[[@CR2]\]\*NA\*\*\*\*52Barber et al. \[[@CR3]\]\*NA\*\*\*\*53.Calderaro et al. \[[@CR4]\]\*\*NA\*\*\*\*64.Camargo-Ayala et al. \[[@CR5]\]\*\*NA\*\*\*\*65.Dhangadamajhi et al. \[[@CR6]\]\*\*NA\*\*\*\*66.Dormond et al. \[[@CR40]\]\*NA\*\*\*\*57.Fuehrer et al. \[[@CR41]\]\*\*NA\*\*\*\*68.Gabrielli et al. \[[@CR42]\]\*\*\*NA\*\*\*\*79.Hopkins et al. \[[@CR22]\]\*□□NA\*\*\*\*710.Jiang et al. \[[@CR43]\]\*NA\*\*\*\*511.Kasehagen et al. \[[@CR11]\]\*\*\*NA\*\*\*\*712.Krishna et al. \[[@CR18]\]\*NA\*\*\*\*513.Lorenzetti et al. \[[@CR44]\]\*NA\*\*\*\*514.Marques et al. \[[@CR45]\]\*\*\*NA\*\*\*\*715.May et al. \[[@CR7]\]\*\*\*NA\*\*\*\*716.Mehlotra et al. \[[@CR13]\]\*\*\*NA\*\*\*\*717.Mehlotra et al. \[[@CR12]\]\*NA\*\*\*\*518.Mueller et al. \[[@CR14]\]\*\*\*NA\*\*\*\*719.Nino et al. \[[@CR46]\]\*\*NA\*\*\*\*620.Pati et al. \[[@CR19]\]\*\*NA\*\*\*\*621.Perandin et al. \[[@CR20]\]\*\*NA\*\*\*\*622.Peruzzi et al. \[[@CR21]\]\*\*NA\*\*\*\*623.Pongvongsa et al. \[[@CR28]\]\*\*\*NA\*\*\*\*724.Putaporntip et al. \[[@CR25]\]\*\*NA\*\*\*\*625.Rubio et al. \[[@CR38]\]\*\*NA\*\*\*\*626.Rubio et al. \[[@CR38]\]\*\*NA\*\*\*\*627.Sitali et al. \[[@CR29]\]\*\*\*NA\*\*\*\*728.Sluydts et al. \[[@CR15]\]\*\*\*NA\*\*\*\*729.Steenkeste et al. \[[@CR16]\]\*\*\*NA\*\*\*\*730.Steenkeste et al. \[[@CR17]\]\*\*\*NA\*\*\*\*731.Subissi et al. \[[@CR23]\]□\*\*NA\*\*\*\*732.Toma et al. \[[@CR27]\]□\*\*NA\*\*\*\*733.Woldearegai et al. \[[@CR47]\]\*\*\*NA\*\*\*\*734.Zhou et al. \[[@CR24]\]\*\*\*NA\*\*\*\*735.Zhou et al. \[[@CR26]\]\*\*NA\*\*\*\*6

The pooled prevalence of triple mixed infection {#Sec10}
-----------------------------------------------

The numbers of triple mixed infection were available for 35 records that included 601 patients from 22 countries. The overall pooled prevalence of triple mixed infection (4%; 95% CI 3--5%; I^2^ = 92.5%) with no evidence of publication bias related to small study effects is shown in the funnel plot (Fig. [2](#Fig2){ref-type="fig"}). The highest prevalence of triple mixed infection for an individual study was 46% (95% CI 37--55) in a study by Zhou et al. \[[@CR24]\].Fig. 2Pooled prevalence of triple mixed infections by *Plasmodium* species

Comparison of the pooled proportion of triple and double mixed infections {#Sec11}
-------------------------------------------------------------------------

The pooled proportion of triple mixed infection compared with double mixed infection was 12% (95% CI 9--18, I^2^ = 91%) (Fig. [3](#Fig3){ref-type="fig"}). Most of the included studies (29/35, 82.9%) presented a lower proportion of triple mixed infection than double mixed infection. Only one study demonstrated a higher proportion of triple mixed infection than double mixed infection \[[@CR24]\]. Another included study by Peruzzi et al. could not input the present meta-analysis because it had only reported on triple mixed infection, not double mixed infection \[[@CR21]\].Fig. 3Pooled proportion of triple mixed infections by *Plasmodium* species compared with double mixed infections

Subgroup analysis {#Sec12}
-----------------

Subgroup analysis of the continents from 34 studies where triple mixed infection were reported in the included studies was available. The analysis demonstrated that the proportion of triple mixed infection was the highest in Oceania 23% (95% CI 15--36%) and Europe 21% (95% CI 5--86%) compared with that of double mixed infection (Fig. [4](#Fig4){ref-type="fig"}). However, the proportion of triple mixed infection was the lowest in America (3%; 95% CI 2--4%). A subgroup difference was found between continents with a high level of heterogeneity (P-value \< 0.0001, I^2^ = 94.8%).Fig. 4Subgroup analysis of triple mixed infections by *Plasmodium* species between areas of the included studies

Subgroup analysis of the febrile subjects and residents from 27 studies was available (Fig. [5](#Fig5){ref-type="fig"}). Compared with the proportion of double mixed infection, triple mixed infection was higher in residents (20%; 95% CI 14--29%) than in febrile patients (7%; 95% CI 4--13%). A subgroup difference was observed between febrile patients and residents with a high level of heterogeneity (P-value = 0.004, I^2^ = 88.2%). Subgroup analysis of the blood collection method for PCR from 32 studies was available. The proportion of triple mixed infection using EDTA blood was 13% (95% CI 8--21%) and dried blood spots was 10% (95% CI 7--17%), with no subgroup difference between the groups (P-value = 0.59; Fig. [6](#Fig6){ref-type="fig"}).Fig. 5Subgroup analysis of triple mixed infections by *Plasmodium* species between residents and febrile groupsFig. 6Subgroup analysis of triple mixed infections by *Plasmodium* species between the two blood collection methods

Seven included studies reported the age groups, and different types of mixed infection (85 triple mixed infection and 581 double mixed infection). Subgroup analysis of age groups demonstrated that, compared with the proportion of double mixed infection, triple mixed infection was lower in patients aged ≤ 5 years (OR = 0.27; 95% CI 0.13--0.56; I^2^ = 31%) and \> 5 years (OR = 0.09; 95% CI 0.04--0.25; I^2^ = 78%) (Fig. [7](#Fig7){ref-type="fig"}). Subgroup analysis demonstrated no statistical difference (P-value = 0.09, I^2^ = 64.7%).Fig. 7Subgroup analysis of triple mixed infections by *Plasmodium* species between the two age groups

Publication bias {#Sec13}
----------------

Publication bias related to study effects was assessed using funnel plot asymmetry, and no publication bias was demonstrated as evidenced by the symmetry of the funnel plot (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Publication bias among the included studies as demonstrated by funnel plot analysis

Discussion {#Sec14}
==========

The pooled prevalence of triple mixed infection has not been clarified in the previous literature. The systematic review and meta-analysis of 12,023 malaria-positive patients demonstrated a high prevalence of triple mixed infection (4%). The most common triple mixed infection of *Plasmodium* species was *P. falciparum*, *P. malariae*, and *P. vivax* (59%). This finding agreed with those of previous studies in Papua New Guinea \[[@CR11]--[@CR14]\], India \[[@CR18]\], Cambodia \[[@CR15]--[@CR17]\], and Thailand \[[@CR24]\], but contradicts the findings of previous studies which included *P. ovale* in triple mixed infection in the Laos-Vietnam border (*P. falciparum*/*P. vivax*/*P. knowlesi*) \[[@CR28]\], China (*P. falciparum*/*P. vivax*/*P. ovale*) \[[@CR26]\], Thailand (*P. falciparum*/*P. vivax*/*P. ovale*) \[[@CR25]\], and Zambia (*P. falciparum*/*P. malariae*/*P. ovale*) \[[@CR29]\].

The mechanisms underlying the triple mixed parasitic infection are unknown; however, the course of an infection might be influenced by the simultaneous occurrence of several *Plasmodium* species \[[@CR30], [@CR31]\]. Another explanation is the immunosuppressive effects caused by chronic *P. falciparum* infection and differences in individual exposure \[[@CR32]\]. Whether the simultaneous infections might be beneficial or adds further detriment to the infected individual is not well defined. Triple mixed infection may be caused by cross immunity-induced susceptibility to three infections or exposure to infective bites of a single vector that can transmit three *Plasmodium* species \[[@CR33]\]. A previous study indicated that infection with one *Plasmodium* species increased susceptibility to infection by other *Plasmodium* species \[[@CR34]\]. The apparent frequency of mixed infection is dependent on the technique used for parasite analyses. The results demonstrated a high proportion of triple mixed infection compared with double mixed infection only in studies using PCR analysis to detect the malaria parasite due to the high sensitivity and specificity of PCR compared with microscopy or RDTs. In areas where more than one *Plasmodium* species is present and transmission is stable, the adult populations often have parasite densities below the level of microscopic detection and called "submicroscopic infections". These submicroscopic infections demonstrated more than one *Plasmodium* species.

The subgroup analysis demonstrated that the proportion of triple mixed infection was higher in residents than in febrile patients, indicating that residents in communities where malaria is endemic were exposed to malaria several times or to more than one species at a time \[[@CR35]\]. These triple mixed infection were submicroscopic infection for which microscopy has insufficient sensitivity for their detection. It is well-documented that malaria patients in endemic areas develop immunity against malaria, resulting in symptom relief \[[@CR35], [@CR36]\]. A previous study demonstrated that age, geographical origin, and clinical manifestations were found to be associated with triple mixed infection \[[@CR5]\]. The subgroup analysis of age ranges demonstrated that the proportion of triple mixed infection was significantly lower across a wide age range of ages compared to double mixed infection. Subgroup analysis demonstrated that no statistical difference in age groups and types of mixed infection. This result suggested that triple mixed infection can occur in both patients aged ≤ 5 years and \> 5 years. However, a limited number of articles have reported on age and susceptibility to triple mixed infection. The included study by Camargo-Ayala et al. showed that patients tend to have a risk of triple mixed infection at an age range of 18--60 years than at ≤ 5 or 5--18 years, whereas patients tend to have a risk of double infection at age range greater than 60 years than at ≤ 5, 5--18 and 18--60 years \[[@CR5]\]. However, small sample sizes of the triple and dual mixed infection were calculated for the risk estimate in the same study. Therefore, the association between age and different types of mixed infection (double and triple infection) should be analysed in further observational studies using the research gap in age and type of mixed infection.

The study demonstrated that vomiting and the intense brown colour of urine were associated with triple mixed infection. Regarding the geographical region analysed, triple mixed infection was mostly found at the Loretoyacu River in the Colombian Amazon region \[[@CR5]\]. The high prevalence of triple mixed infection at the Loretoyacu River may be due to the occurrence of the mosquito *Anopheles maculatus*, which can serve as a single vector for *P. falciparum*/*P. vivax*/*P. malariae* \[[@CR5]\]. Triple species infection of *P. falciparum* and *P. malariae*, followed by *P. ovale* delayed infection, were also observed in two adopted children from the Central African Republic and may be attributed to late therapeutic failure or the relatively insufficient dosage due to increased oral clearance of atovaquone in paediatric patients \[[@CR37]\].

The subgroup analysis demonstrated that the proportion of triple mixed infection was the highest in Oceania (23%) and Europe (21%) but the lowest in America. A previous study indicated that, in Oceania, where intense transmission occurs in very small focal forests or forest fringe areas, mixed infection are common but require submicroscopic detection \[[@CR9]\]. Malaria disease in Europe has been mostly eradicated, but the increase in the number of imported malaria due to tourism, as well as population migration, resulted in increased mortality, from 3.8 to 20% \[[@CR38]\]. These imported cases have increased the number of malaria cases in places where its transmission was low or previously eradicated, such as in Europe \[[@CR39]\].

Knowledge about mixed infection is important not only to develop appropriate control measures but also for therapeutic options. For example, if *P. vivax* infection is suppressed by mixed infection with *P. falciparum*, effective control of *P. falciparum* infection in an area will activate *P. vivax* transmission in the community, a condition that is more difficult to control \[[@CR17]\]. The present study was limited by the heterogeneity of the included studies and should be interpreted cautiously. Thus, the findings of the present study might not necessarily apply to all co-endemic regions. The present study could not extract the age of patients with triple mixed infection due to the lack of data reported in the included studies. Moreover, the clinical data, laboratory data, and treatment data of individual patients with triple mixed infection were also unavailable to extract. These data should be included and declared in malaria studies for its apparent value in cases of review and meta-analyses. Future meta-analyses should assess the cases reported or case series to provide a greater understanding of the factors associated with triple mixed infection.

Conclusion {#Sec15}
==========

In summary, although mixed infection was recognized, the prevalence of triple mixed infection was high (4%). The proportion of triple mixed infection was the highest in Oceania and Europe but lower in America. Compared with the proportion of double mixed infection, triple mixed infection was higher in residents (20%) than in febrile patients (7%). The findings suggested that in some regions, co-endemic for triple mixed infection, PCR, or molecular diagnosis for all residents in communities where malaria is endemic can provide prevalence data and intervention measures, as well as prevent disease transmissions and enhance malaria elimination efforts.
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CI

:   Confidence interval

DNA

:   Deoxyribonucleic acid

NOS

:   Newcastle--Ottawa Scale

OR

:   Odds ratio

PCR

:   Polymerase chain reaction

PRISMA

:   Preferred reporting items for systematic reviews and meta-analyses

RDT

:   Rapid diagnostic test

WHO

:   World Health Organization
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